To jointly develop humanoid robotics and embodied intelligence technologies for applications in pharmaceutical manufacturing, packaging, quality control, logistics, and other scenarios.
Based on practical needs, to support the integration of embodied intelligent robotic products and services into Bayer Pharmaceuticals’ production lines.
Shanghai, November 6, 2025 — During the eighth China International Import Expo (CIIE), Bayer HealthCare Co., Ltd. (Bayer) and Beijing Humanoid Robotics Innovation Center Co. Ltd. (X- Humanoid) signed a collaboration agreement, pledging to jointly advance the technological development of humanoid robots and embodied intelligence technology capabilities in the area of pharmaceutical solids production, packaging, quality control, warehousing and distribution scenarios.
“Bayer Pharmaceuticals’ mission is to ‘treat the untreatable, cure disease, and offer hope,’ and product supply achieves this goal by focusing on high quality and efficiency,” said Christopher J. Grail, Senior Vice President and Global Head of Engineering at Bayer Pharmaceuticals. “X-Humanoid is a like-minded technology partner of Bayer. We look forward to working with X-Humanoid to develop robotic solutions, explore the infinite potential of new technologies, and ultimately benefit patients.”
“The collaboration between X-Humanoid and Bayer is a landmark in the innovative development of both companies, and more importantly, an exemplary case of win-win cooperation between embodied AI and biomedical science,” said Youjun Xiong, CEO of X-Humanoid. “We are committed to developing the fastest, the most intelligent, and most practical embodied AI robots to foster the cross-industry integration of 'smart technology and pharmaceutical manufacturing'. This partnership will not only accelerate the technological maturation and deployment of embodied AI robots in high-standard, stringent industrial environments but will also inject vital innovation into ensuring drug supply and enhancing global health outcomes.”
Under the agreement, Bayer and X-Humanoid will explore the stability and compatibility of emerging robotic technologies, evaluate their potential applications in pharmaceutical manufacturing processes, and assess their value creation potential and limitations of pharmaceutical operations.
Additionally, both parties will collaborate in the field of “robotics + high-end manufacturing,” focusing on practical needs such as material handling, quality monitoring, and product packaging. This partnership will facilitate the integration of embodied intelligent robotics products and services into Bayer Pharmaceuticals’ production lines.
Embodied intelligence is a high-quality, high-performance intelligent system capable of responding rapidly and accurately under highly changing conditions, and humanoid robots are an important carrier of embodied intelligence technology . As a cutting-edge topic in the area of artificial intelligence, embodied intelligence is gradually moving from theory to practice, and from the laboratory to reality. This year, the Chinese government’s work report proposed for the first time to establish a growth mechanism for future industry investment and cultivate future industries such as bio-manufacturing, quantum technology, embodied intelligence, and 6G.
Reference
“Ten Trends in Humanoid Robots: A Outlook”, released at the World Robot Conference 2024
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com.
About X-Humanoid
Established in November 2023, X-Humanoid is China’s first full-stack technology company dedicated to embodied intelligence, encompassing both hardware and software. The company focuses on the core technologies, product development, and application deployment of embodied AI robots. It has developed the universal robot platform “Embodied Tien Kung” and the universal embodied AI platform “HuiSi KaiWu”. Continuously striving to create the “fastest, most intelligent, and most practical” embodied AI robots, it has achieved several remarkable feats. These include winning the world's first humanoid robot half-marathon, claiming the title of the first robotic “sprinting champion” in history by winning the 100-meter race, and securing the championship in the object handling event at the World Humanoid Robot Games. The company is persistently exploring and deploying robots in high-value application scenarios such as industrial manufacturing, specialized operations, and pharmaceuticals, with the ultimate goal of making robots truly intelligent partners in human production and daily life.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
